Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Information, Expiry & Status of FDA Orange Book Patents covering Alunex

Client Email

Product

Alunex
US Patents

Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Alunex

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

43 API Suppliers, 14 USDMF, 2 JDMF, 5 EU WC, 6 KDMF, 12 NDC API, 28 Listed Suppliers, $ API Reference Price

43 API Suppliers
14 USDMF
2 JDMF
5 EU WC
6 KDMF
12 NDC API
28 Listed Suppliers
$ API Reference Price

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

API Reference Price
API Exports
API Imports
FDF Exports
FDF Imports

FINISHED DOSAGE FORMULATIONS

203 FDF Dossiers, 66 FDA Orange Book, 8 Europe, 34 Canada, 26 South Africa, 69 Listed Dossiers

203 FDF Dossiers
66 FDA Orange Book
8 Europe
34 Canada
26 South Africa
69 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;ORAL - 4MG/5ML;5MG/5ML, TABLET;ORAL - 2MG;200MG;30MG, TABLET;ORAL - 4MG;200MG;10MG, SOLUTION;ORAL - 4MG/5ML;5MG/5ML;60MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 12MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;ORAL - 4MG/5ML;5MG/5ML
TABLET;ORAL - 2MG;200MG;30MG
TABLET;ORAL - 4MG;200MG;10MG
SOLUTION;ORAL - 4MG/5ML;5MG/5ML;60MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 12MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Minakem, 1 Evonik, 12 Rochem International Inc, 23 SPI Pharma, 2 Seqens, 27 DKSH, 2 Jai Radhe Sales, 3 Pharm-RX Chemical, 10 Boai NKY Pharmaceuticals Ltd, 17 Gangwal Healthcare, 2 Kewpie Corporation, 15 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 14 Actylis, 3 Aeon Procare, 2 Alcedo Pharmachem, 12 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 37 BASF, 1 Bioplus Life Sciences, 5 Clariant, 14 Corel Pharma Chem, 7 DFE Pharma, 2 Finar, 14 Gangwal Chemicals, 11 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 39 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 22 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 4 Novo Excipients, 4 Pharmatrans-Sanaq, 10 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 47 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 3 The Dow Chemical Company, 4 Ulanqab Kema New Material, 2 Valens Pharmachem, 5 Vasa Pharmachem, 1 Vertellus, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

124 Fillers, Diluents & Binders, 73 Coating Systems & Additives, 63 Thickeners and Stabilizers, 55 Direct Compression, 52 Solubilizers, 45 Taste Masking, 44 Disintegrants & Superdisintegrants, 43 Controlled & Modified Release, 34 Topical, 33 Granulation, 33 Parenteral, 31 Film Formers & Plasticizers, 29 Lubricants & Glidants, 22 Chewable & Orodispersible Aids, 22 Co-Processed Excipients, 17 Rheology Modifiers, 16 Emulsifying Agents, 13 API Stability Enhancers, 9 Empty Capsules, 6 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

124 Fillers, Diluents & Binders
73 Coating Systems & Additives
63 Thickeners and Stabilizers
55 Direct Compression
52 Solubilizers
45 Taste Masking
44 Disintegrants & Superdisintegrants
43 Controlled & Modified Release
34 Topical
33 Granulation
33 Parenteral
31 Film Formers & Plasticizers
29 Lubricants & Glidants
22 Chewable & Orodispersible Aids
22 Co-Processed Excipients
17 Rheology Modifiers
16 Emulsifying Agents
13 API Stability Enhancers
9 Empty Capsules
6 Surfactant & Foaming Agents
5 Coloring Agents
4 Vegetarian Capsules
1 Soft Gelatin

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 18 NEWS #PharmaBuzz

2 DATA COMPILATION #PharmaFlow
18 NEWS #PharmaBuzz

MARKET PLACE

25 APIs, 3 FDF Dossiers

25 APIs
3 FDF Dossiers

PATENTS & EXCLUSIVITIES

4 US Patents

4 US Patents

REF. STANDARDS & IMPURITIES

1 USP, 8 JP, 1 Others

1 USP
8 JP
1 Others

$ API Ref.Price (USD/KG) : 40 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

4 All

01 2HALEON US HOLDINGS

02 2MAINPOINTE

filter Patent Number Reset all filters

4 All

01 17863287

02 19066942

03 19107921

04 110238640

filter API Patent Reset all filters

4 All

01 4Blank

filter FDF Patent Reset all filters

4 All

01 3Y

02 1Blank

filter Expiration Date Reset all filters

4 All

01 12024-05-25

02 12027-02-28

03 22032-01-03

Product Main Page

01

HALEON US HOLDINGS

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

AAPS 2024

Not Confirmed

HALEON US HOLDINGS

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-02-28

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

US Patent Number : 7863287

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 21441

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2027-02-28

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

HALEON US HOLDINGS

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

AAPS 2024

Not Confirmed

HALEON US HOLDINGS

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-05-25

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

US Patent Number : 10238640

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 21587

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2024-05-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

MAINPOINTE

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

AAPS 2024

Not Confirmed

MAINPOINTE

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-01-03

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

US Patent Number : 9066942

Drug Substance Claim :

Drug Product Claim :

Application Number : 206323

Patent Use Code : U-1716

Delist Requested :

Patent Use Description : TREATMENT OF COUGH AND...

Patent Expiration Date : 2032-01-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

MAINPOINTE

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

AAPS 2024

Not Confirmed

MAINPOINTE

AAPS 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-01-03

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

US Patent Number : 9107921

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 206323

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-01-03

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?